CPI-0209, a second-generation enhancer of zeste homolog 2 (EZH2) inhibitor, is in phase 2 development for hematological malignancies and solid tumors by Constellation. (RTTNews) - Royalty Pharma plc (RPRX) said that it has reached a $2.025 billion strategic funding partnership with MorphoSys AG (MOR), as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (CNST). The funding partnership is anchored by Royalty Pharma's acquisition of MorphoSys' rights to receive future royalties on Janssen's Tremfya (guselkumab).